Peptide Marker Scoring for Personalized Therapy Regimen Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to predict treatment success and identify suitable therapeutic regimens for individuals based on urinary peptidomic profiles, lacking the ability to assess the impact of active agents on disease progression and treatment efficacy.
Innovation Solution
A method involving peptidome/proteome analysis of body fluid samples to determine a reference value and score for peptide/protein markers, using a database to predict treatment success and therapeutic regimens by comparing the impact of active agents on these markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptidome/proteome analysis is performed to determine treatment success and identify therapeutic regimens, then personalized treatment prediction capability is improved, but method complexity and data processing requirements increase
Solution Approach 1:
The method segments the complex peptidome/proteome data into a focused panel of specific peptide/protein markers with known disease associations. By analyzing only these predetermined markers rather than the entire peptidome, the method maintains high prediction accuracy while reducing computational complexity and data processing requirements.
Solution Approach 2:
The method transforms complex peptidome/proteome data into simplified quantitative parameters (marker concentrations, reference values, and scores) that can be easily compared and processed. This parameter transformation enables straightforward prediction of treatment success and identification of therapeutic regimens without requiring complex analytical frameworks.
2Measurement precision
If a comprehensive peptidome/proteome profile is analyzed to predict treatment outcomes, then prediction accuracy is improved, but analysis time and computational resources increase
Solution Approach 1:
The method extracts and focuses only on the most relevant peptide/protein markers from the comprehensive peptidome/proteome profile. By taking out only these specific markers that have established associations with vascular diseases and treatment responses, the method achieves high prediction accuracy while significantly reducing analysis time and computational resource requirements.
Solution Approach 2:
The method performs preliminary identification and validation of disease-associated peptide/protein markers before clinical application. This preliminary action creates a predefined panel of markers that can be rapidly analyzed in clinical settings, eliminating the need for time-consuming comprehensive peptidome/proteome analysis while maintaining high prediction accuracy.
3Adaptability or versatility
If reference values and scores are calculated from database information to determine therapy regimens, then personalized treatment planning is improved, but data processing complexity increases
Solution Approach 1:
The method transforms complex database information into simplified reference values and scores for specific peptide/protein markers. By changing the data parameters from raw peptidome/proteome profiles to standardized marker concentrations and calculated scores, the method enables personalized treatment planning through straightforward comparisons while reducing data processing complexity.
Solution Approach 2:
The method creates simplified copies (reference values and scores) of the complex database information containing disease-associated marker profiles. These copied parameters can be easily stored, compared, and processed to determine personalized therapy regimens without requiring access to or processing of the entire complex database.
Data Source
AI summary
The present invention relates in a first aspect to a method for determining the therapy regimen and/or the treatment success of a treatment of an individual either prophylactically or therapeutically with an active agent, whereby the peptidome/proteome in a body fluid sample from the individual is determined and a reference value is calculated based on processing the information of a predetermined group of peptide/protein markers present in the peptidome/proteome determined in said individual and determining a score for the same predetermined group of peptide/protein markers, whereby the score is calculated by processing information for each marker of the group obtained under the impact of the active agent whereby the information is present in a database and processing the value of the individual with the score, thus, determining a therapy regimen and/or predicting the treatment success with the active agent based on the processing. That is, the method allows to predict whether an active agent is beneficial or not or may even have adverse effects for the treatment of the individual to be analysed. The method is particularly useful in predicting firstly a possible very relevant health event and secondly determining possible preventive treatment to counteract the possible very relevant health event in the future. In addition, a computer implemented method is provided as well as a computer readable medium or computer program product and the use of a test kit with the method according to the present invention.